Skip to main content

William K. Warren Foundation Archives

Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment

Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.

Read more


Investigational new drug for Alzheimer’s scheduled for first study in humans

Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.

Read more


Foundation’s support speeds search for new schizophrenia drugs at Vanderbilt

Aug. 15, 2016—Research in the Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) aimed at developing innovative new treatments for schizophrenia just received a powerful assist from The William K. Warren Foundation.

Read more


Grant enhances mental illness drug research efforts

Jul. 16, 2015—Research at Vanderbilt University Medical Center aimed at developing potential new treatments for major depressive disorder, general anxiety disorder and post-traumatic stress disorder got a big boost this week from The William K. Warren Foundation of Tulsa, Oklahoma.

Read more


Grant spurs schizophrenia research

Feb. 12, 2015—Vanderbilt University is partnering with the William K. Warren Foundation of Tulsa, Oklahoma, on research aimed at improving the treatment of schizophrenia and other forms of serious mental illness.

Read more


Event celebrates Vanderbilt endowed chair holders

Aug. 30, 2012—Twelve Vanderbilt University faculty members were honored for extraordinary contributions to their respective fields during an Aug. 28 celebration of endowed chair holders at the Student Life Center.

Read more